REGN Regeneron Pharmaceuticals Inc.

341.99
-3.29  -1%
Previous Close 345.28
Open 341.2
Price To Book 3.58
Market Cap 37,549,053,330
Shares 109,795,764
Volume 496,799
Short Ratio
Av. Daily Volume 793,753
Stock charts supplied by TradingView

NewsSee all news

  1. Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020

    TARRYTOWN, N.Y. and WASHINGTON, Jan. 22, 2020 /PRNewswire/ -- Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors Females represent more than 50

  2. Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020

    TARRYTOWN, N.Y., Jan. 10, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday,

  3. Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease

    TARRYTOWN, N.Y., Jan. 9, 2020 /PRNewswire/ --  Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia

  4. Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy

    TARRYTOWN, N.Y., Jan. 8, 2020 /PRNewswire/ -- Preclinical results published in Science Translational Medicine show that adding CD28 costimulatory bispecifics to CD3 bispecifics led to synergistic anti-tumor activity

  5. Regeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    TARRYTOWN, N.Y., Dec. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020.  The

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
FDA Approval announced August 17, 2018.
EYLEA
Wet AMD
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
sBLA filing due 4Q 2019. Moved to 1Q 2020 due to no update.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
FDA approval announced April 26, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 interim analysis November 5, 2019 noted trial to continue as planned. Next interim look due 2020.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only.
Fasinumab
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 data released August 14, 2017 - primary endpoint not met.
REGN2222
Respiratory syncytial virus (RSV)
FDA Approval announced May 13, 2019.
EYLEA - PANAROMA
Nonproliferative Diabetic Retinopathy
Phase 3 ongoing.
EYLEA - PROTOCOL-W
Diabetic Retinopathy
Phase 3 data due 2020.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
FDA Approval announced June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.
Fasinumab
Osteoarthritis and chronic low back pain
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 data due 2020.
Dupixent (dupilumab)
Peanut Allergy
Phase 2 portion of Phase 2/3 trial due 2020.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 1 updated data at ASH December 2019.
REGN1979
Follicular Lymphoma
BLA filing due mid-2020.
Evinacumab (ANGPTL3 Antibody)
Homozygous familial hypercholesterolemia (HoFH)
Phase 2 data June 21, 2019 met primary endpoint vs placebo. No increased benefit compared to Dupixent.
SAR440340 (REGN3500)
Asthma
Phase 2 data due 3Q 2020.
SAR440340 / REGN3500
Atopic dermatitis
Phase 2 pivotal data due 2H 2020.
Cemiplimab
Basal cell carcinoma
Phase 3 enrolment to be completed 2H 2020.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 2 interim data due 2020.
Pozelimab (REGN3918)
Paroxysmal nocturnal hemoglobinuria (PNH
Phase 2 trial did not meet primary endpoint p=0.07 - January 9, 2020. Patient-reported flare-ups were reduced by 50% (nominal p=0.03).
Garetosmab
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. Forty of the Nation's Brightest Young Scientists Named Finalists in Regeneron Science Talent Search 2020

    TARRYTOWN, N.Y. and WASHINGTON, Jan. 22, 2020 /PRNewswire/ -- Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors Females represent more than 50

  2. Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020

    TARRYTOWN, N.Y., Jan. 10, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday,

  3. Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease

    TARRYTOWN, N.Y., Jan. 9, 2020 /PRNewswire/ --  Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia

  4. Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy

    TARRYTOWN, N.Y., Jan. 8, 2020 /PRNewswire/ -- Preclinical results published in Science Translational Medicine show that adding CD28 costimulatory bispecifics to CD3 bispecifics led to synergistic anti-tumor activity

  5. Regeneron Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    TARRYTOWN, N.Y., Dec. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020.  The

  6. Society for Science & the Public Announces Regeneron as New Title Sponsor of the International Science and Engineering Fair

    TARRYTOWN, N.Y. and WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Regeneron ISEF gathers outstanding science students from around the globe to compete for millions in prizes at the world's largest pre-college science

  7. Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

    Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron

  8. Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

    TARRYTOWN, N.Y. and PARIS, Dec. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced their intent to simplify their antibody collaboration for Kevzara® (sarilumab) and

  9. First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma

    TARRYTOWN, N.Y., Dec. 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory

  10. Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

    TARRYTOWN, N.Y., Dec. 5, 2019 /PRNewswire/ -- Results from initial 6-patient cohort show pozelimab reduced lactate dehydrogenase (LDH) to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria

  11. New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths

    TARRYTOWN, N.Y., Nov. 27, 2019 /PRNewswire/ -- Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received

  12. Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton Award

    TARRYTOWN, N.Y., Nov. 22, 2019 /PRNewswire/ -- Columbia's highest honor bestowed for Yancopoulos' contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that George D.

  13. Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y., Nov. 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast management presentations as follows: Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day, at 11:15 a.m.

  14. Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

    TARRYTOWN, N.Y. and ROCHESTER, Minn., Nov. 6, 2019 /PRNewswire/ -- Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration

  15. Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

    80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pa., Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today

  16. Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

    TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as

  17. Regeneron Reports Third Quarter 2019 Financial and Operating Results

    TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Third quarter 2019 revenues increased 23% to $2.05 billion versus third quarter 2018 Third quarter EYLEA® U.S. net sales increased 16% to $1.19 billion versus third quarter

  18. Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

    Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis First biologic approved in the European Union for adults with severe chronic rhinosinusitis with nasal

  19. Regeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For

    TARRYTOWN, N.Y., Oct. 25, 2019 /PRNewswire/ --  Regeneron is the most highly ranked company over the past decade Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as a

  20. Regeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good

    TARRYTOWN, N.Y., Oct. 25, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today celebrates its third annual Day for Doing Good, a company-wide global day of service. Reflecting Regeneron's

  21. Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y., Oct. 18, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows: Credit Suisse 28th Annual Healthcare Conference at 10:00 a.m. EST

  22. Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019

    TARRYTOWN, N.Y., Oct. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 5, 2019,

  23. The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published detailed positive results from two Phase 3

  24. Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis

    CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis   PARIS and TARRYTOWN, NY – September 20, 2019 – The European Medicines Agency's Committee for Medicinal

  25. CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis

    TARRYTOWN, N.Y. and PARIS, Sept. 20, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use

  26. Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis

    TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Sept. 18, 2019 /PRNewswire/ --  Understand AD program brings together a team of experts to help a teen with severe atopic dermatitis (AD) and his parents navigate the

  27. Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies

    TARRYTOWN, N.Y., Sept. 17, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was added to the Dow Jones Sustainability World Index (DJSI World) for the first time.

  28. Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9

    U.S. District Court invalidates Amgen patent claims targeting PCSK9 Court rules in favor of Sanofi and Regeneron in ongoing Praluent® (alirocumab) patent litigation PARIS and TARRYTOWN, NY – August 28, 2019 –

  29. U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9

    TARRYTOWN, N.Y. and PARIS, Aug. 28, 2019 /PRNewswire/ -- Court rules in favor of Regeneron and Sanofi in ongoing Praluent® (alirocumab) patent litigation  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi